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Abstract
Background—Controversy exists about the incremental utility of nontraditional lipid biomarkers 
[e.g., apolipoprotein (apo) B, apo A-I, and non-HDL-C] in improving cardiovascular disease 
(CVD) risk prediction when added to a conventional model of traditional risk factors (e.g., total 
cholesterol, LDL cholesterol, HDL cholesterol, sex, age, smoking status, and blood pressure). 
Here we present a systematic review that was conducted to assess the use of nontraditional lipid 
biomarkers including apo B, apo A-I, apo B/A-I ratio, and non-HDL-C in improving CVD risk 
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prediction after controlling for the traditional risk factors in populations at risk for cardiovascular 
events.
Content—This systematic review used the Laboratory Medicine Best Practices (LMBP™) A-6 
methods. A total of 9 relevant studies published before and including July 2015 comprised the 
evidence base for this review. Results from this systematic review indicated that after the 
adjustment for standard nonlipid and lipid CVD risk factors, nontraditional apolipoprotein 
biomarkers apo B (overall effect = relative risk: 1.31; 95% CI, 1.22–1.40; 4 studies) and apo B/apo 
A-I ratio (overall effect = relative risk: 1.31; 95% CI, 1.11–1.38; 7 studies) resulted in significant 
improvement in long-term CVD risk assessment.
Summary—Available evidence showed that nontraditional lipid biomarkers apo B and apo B/apo 
I ratio can improve the risk prediction for cardiovascular events after controlling for the traditional 
risk factors for the populations at risk. However, because of insufficient evidence, no conclusions 
could be made for the effectiveness of apo A-I and non-HDL-C lipid markers to predict the CVD 
events, indicating a need for more research in this field.
Cardiovascular disease (CVD)8 remains the leading cause of death and inpatient hospital 
care in the United States (1–4). Research has shown that approximately 50% of population-
attributable risk of developing CVD is associated with abnormalities in lipid biomarker 
profile (5). Most of the existing guidelines have used traditional lipid levels and other risk 
factors, namely total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-
C), triglycerides (TG), and nonlipid risk factors, e.g., high blood pressure, cigarette 
smoking, diabetes, age, sex, diet, and obesity, as risk factor scores for CVD risk prediction 
(6, 7). Based on recent studies, there is a growing interest to investigate whether 
nontraditional lipid-related markers add incremental value to standard prognostic models 
containing information on TC, HDL-C, and other conventional risk factors and can improve 
the CVD risk prediction (5). The utility of nontraditional markers in risk assessment is best 
examined by combining them with a model that includes traditional risk factors (8, 9). Non-
HDL cholesterol (non-HDL-C), apolipoprotein (apo) B, and apo A-I are among the most 
investigated nontraditional lipid biomarkers and hence were the focus of this study (10–12).
QUALITY GAP: LIPID BIOMARKERS AND CVD RISK
Traditional risk factors provide estimates of plasma pool sizes and do not necessarily relate 
to the flux of cholesterol between lipoproteins and tissues, which may be more relevant to 
the process of atherosclerosis. Controversy exists about the effectiveness of traditional lipid 
tests to accurately predict risk of cardiovascular events, causing potential for missed 
opportunities for prevention and leading to suboptimal clinical management because these 
do not (a) account for the variability in cholesterol subfraction content, (b) measure 
lipoprotein particle size and number, or (c) provide information suggestive of changes 
associated with insulin resistance progression. Two major trends may be further 
compromising the ability of LDL-C to serve as the best surrogate for atherogenic lipo-
proteins to target CVD risk reduction. First, the prevalence of obesity in the US remains high 
8Nonstandard abbreviations: CVD, cardiovascular disease; TC, total cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL 
cholesterol; TG, triglycerides; apo, apolipoprotein; LMBP, Laboratory Medicine Best Practices; ATP, Adult Treatment Panel.
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(13), leading to a higher prevalence of mixed dyslipidemia and more discrepancies between 
LDL-C and other lipoproteins such as apo B, LDL particle number, and non-HDL-C (14–
16). Second, evidence suggests that even when LDL-C is within the normal range, 
significant residual cardiovascular risk remains (17). Because a majority of patients on 
conventional lipid-lowering treatment have either diabetes or some component of the 
metabolic syndrome, there is an increasing need to identify the degree of residual 
cardiovascular risk (14–16, 18–20).
The objective of this review was to evaluate the available evidence to compare the 
incremental utility of apolipoprotein and non-HDL lipid bio-markers to the traditional lipid 
measures (e.g., TC, TG, HDL-C) and other nonlipid standard risk factors (e.g., smoking 
status, high blood pressure, type 2 diabetes) for risk prediction of CVD events. For the 
purposes of this review, cardiovascular events of interest included ischemic heart disease, 
congestive heart failure, stable angina, unstable angina, myocardial infarction, and CVD 
death.
DESCRIPTION OF EVALUATED PRACTICES
This review evaluated the effectiveness of the following 4 biomarkers (practices) to improve 
the prediction of CVD events when added to traditional lipid biomarkers (e.g., TC, HDL-C): 
(i) apo B; (ii) apo A-I; (iii) apo B/apo A-I ratio; and (iv) non-HDL cholesterol (non-HDL-C).
Apo B
Apo B is the primary apolipoprotein of chylomicrons, VLDL, intermediate-density 
lipoprotein, and LDL particles (14, 21, 22). Importantly, there is 1 apo B-100 molecule per 
hepatic-derived lipoprotein; hence, measurement of apo B can quantify the number of 
lipoprotein particles by noting the total apo B-100 concentration in the circulation (more 
specific to LDL particle concentration) (23). Furthermore, high levels of apo B are indicative 
of a higher risk even when LDL-C or non-HDL-C levels commonly stay low in highly 
atherogenic states such as the metabolic syndrome and type 2 diabetes (24, 25). Prospective 
studies suggest that concentrations of apo B are superior indicators of vascular/heart disease 
and CVD risk prediction than standard lipid profile, e.g., TC and LDL-C (22, 26–31).
Apo A-I
Apo A-I is the major apolipoprotein in the HDL particles (32), accounting for 70% of all 
HDL-associated proteins (16) and mediates many of the anti-atherogenic functions of HDL 
(33). HDL-C levels are inversely correlated with risk for CVD, but HDL-C is heterogeneous 
in composition and size and varies widely across patients; thus, apo A-I is potentially more 
accurate than HDL-C in reflecting the “atheroprotective” potential of lipid metabolism (16, 
18, 32).
Apo B/A-I ratio
The apolipoprotein B/A-I ratio is used as a measure of the proatherogenic to anti-
atherogenic cholesterol (34). It was found to be strongly associated with CVD risk, (16, 29, 
35, 36) and in some cases more than that of other cholesterol ratios (34, 36). Furthermore, 
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compared to other lipid ratios, apolipoprotein B/A-I ratio may be more accurate in risk 
prediction, particularly among high-risk individuals (37).
Non-HDL-C
Non-HDL-C is the difference between the TC concentration and the HDL-C concentration, 
providing an estimate of cholesterol in the atherogenic particles including intermediate-
density lipoprotein, VLDL, lipoprotein(a), and LDL (31, 38). Although the CVD risk 
prediction is based on the increased concentrations of TC (39, 40), mostly from increased 
LDL-C, research has shown the utility of non-HDL-C in the prevention of CVD (41) and 
varying CVD risk prediction across several studies (11, 18, 25, 28, 31, 36, 42). The latest 
guidelines for both European and American Cardiological Societies emphasize the 
importance of this parameter for assessing the risk of atherosclerosis and coronary heart 
disease.
METHODS
This systematic evidence review was conducted using the Laboratory Medicine Best 
Practices (LMBP) Initiative's “A-6” systematic review methods, which is reported in detail 
elsewhere (43) (LMBP™ website). In brief, the process includes formation of a review team 
that includes a review coordinator, data abstractors, CDC liaison, and subject matter experts 
(expert panel team) with the expertise in the area of cardiovascular medicine, laboratory 
management, and evidence review methods. The team worked under the oversight of the 
LMBP Workgroup. Supplemental Appendix A lists the members of the expert panel team 
for this review; see the Data Supplement that accompanies the online version of this article 
at http://www.jalm.org/content/vol1/issue2. The results of the evidence-based best practice 
are presented to and approved by the LMBP Work-group team (Supplemental Appendix B 
lists the LMBP Workgroup members; see the online Data Supplement).
Ask (A-1): review question and analytic framework
Review question—What practices are effective at improving the risk prediction (or risk 
estimation) for CVD events among the populations at risk, specifically ischemic heart 
disease, congestive heart failure, angina, myocardial infarction, and CVD death, when 
supplemented to the traditional lipid (e.g., TC, LDL, TG, and HDL) and nonlipid (e.g., age, 
sex, smoking status, and blood pressure) risk factors?
This review question is addressed in the context of an analytic framework as depicted in Fig. 
1.
The following were the relevant Population, Intervention/Practice, Comparator, and 
Outcome (PICO) elements considered for this review.
Population
• Men (>35 years)
• Women (>45 years)
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• Younger adults (≥20 years) with multiple cardiovascular risk factors for 
CVD
• No previously diagnosed CVD or diabetes at baseline
• In ambulatory (including primary, specialty care) and inpatient settings
Interventions: Practices using nonstandard lipo-protein measurements in addition to the 
existing traditional risk factors (e.g., TC, TG, LDL-C, HDL-C, age, sex, smoking status, and 
blood pressure) for calculating cardiovascular risk assessment. The following lipid 
biomarkers were considered for this review:
• Apo B
• Apo A-I
• Apo B/apo A-I ratio
• Non-HDL-C
Comparison: Practices using traditional risk factors (e.g., TC and HDL-C, age, sex, 
smoking status, and blood pressure) alone to calculate CVD risk prediction.
Outcome: Improvement in the 10-year risk prediction of CVD events (e.g., myocardial 
infarction, ischemic heart disease, and CVD death) upon adding the nonstandard biomarker. 
Studies with follow-up period <10 years were still included in the review but were penalized 
in the study quality rating because of type 1 censoring of the findings (44).
Inclusion/exclusion criteria for studies to be included in this review
Inclusion criteria—To meet the eligibility criteria for this review, a study had to (a) 
address one or more of the proposed practices of interest in the context of CVD outcomes; 
(b) target populations in the studies who met the population criteria—that is, at-risk 
populations described above, with no previously diagnosed CVD or diabetes; (c) report the 
outcome(s) of interest—that is, improvement in the 10-year risk prediction of CVD events 
(e.g., myocardial infarction, CVD death) due to the addition of 1 of the 4 practices; and (d) 
provide comparison data to calculate the effectiveness of practices of interest (e.g., pre- and 
post-intervention data, concurrent comparison data).
In addition, interventions were considered to be included in this review if the biomarker of 
interest was added to a model or algorithm of the traditional lipid profile (e.g., TC, TG, 
HDL-C) and other risk factor (e.g., high blood pressure, cigarette smoking, diabetes, family 
history of premature heart disease, age, sex, diet, obesity, and physical inactivity) for 
predicting CVD risk. The practices were considered individually (e.g., the combination of 
apo B and non-HDL-C simultaneously added into a model was not considered a practice of 
interest), unless the results for the effectiveness of each practice was reported separately. A 
practice was considered effective if the fit of a model containing all traditional risk factors 
was significantly improved through the addition of a practice.
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Exclusion criteria—The exclusion criteria were as follows: (a) previously diagnosed 
CVD or symptomatic coronary artery disease at baseline and (b) previously diagnosed 
diabetes at baseline.
Acquire (A-2): search for evidence
A comprehensive electronic literature search was conducted to retrieve the relevant evidence 
published before and including July 2015. Three databases were used for a formal literature 
search: PubMed, CINAHL, and EMBASE (focusing on international biomedical literature). 
Details of the formal literature search strategy can be found in Supplemental Appendix C 
(see the online Data Supplement). In addition, the systematic review team used other sources 
to locate relevant studies including hand searches (e.g., the citations from retrieved studies, 
Google scholar) and referrals from the experts in the field (e.g., expert panel team). To 
collect relevant unpublished data, researchers in the field, laboratories, and institutions were 
invited through personal requests and the LMBP website, but the review team did not 
receive any relevant unpublished data to be included in this review.
Appraise (A-3): screening, data abstraction, and quality scoring of individual studies
During the initial screening process, studies were excluded if they did not satisfy the 
inclusion criteria for this review as described in a previous section. Each eligible study was 
abstracted and assessed for quality of execution by 2 independent reviewers. Data 
abstraction was conducted by using the standardized LMBP abstraction methods and 
abstraction form. All differences were resolved through consensus. After the full abstraction, 
each study was evaluated for quality scoring to minimize any issue related to internal and 
external validity using LMBP quality assessment methods (43).
Details on the rating process of individual studies can be found elsewhere (43). Each study 
was classified into 1 of 3 quality ratings: good (8–10 score), fair (5–7 score), and poor (≤4 
score). Studies with poor quality ratings were excluded from the effect size metaanalyses 
and the overall practice evidence base. See Supplemental Appendix D (in the online Data 
Supplement) for the Evidence Summary Tables containing quality ratings for each study.
Analyze (A-4): summarization of results and strength of the effect magnitude
Results from all included studies were variously reported risk ratios: odds ratios, relative 
risks, or hazard ratios. For the analyses purposes, these ratios were assumed to approximate 
the same measure of relative risk. Metaanalysis was performed to calculate the overall grand 
mean effect recommended by Borenstein et al. (45). A random-effects model was used for 
these statistics to perform meta-analysis because (a) not all the studies compared the same 
mixture of nontraditional lipid biomarkers to the traditional risk factors to improve the CVD 
risk prediction and (b) the long-term CVD risk prediction was based on different clinical 
CVD events in individual studies. To evaluate the effectiveness of these interventions, 
pooled point estimates across studies were expressed as an overall grand mean with CIs. 
When possible, all metaanalysis results were presented as forest plots, where the vertical line 
labeled “1” equals “no/minimal” difference between practices, and estimates to the right of 
the line favor the tested practice, i.e., improved risk prediction of CVD events due to the 
assessed practice. However, as apo A-I levels inversely correlate with risk for CVD (i.e., 
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high apo A-I levels are protective against future cardiovascular events), the effect estimates 
less than 1 were considered favorable for development of CVD risk prediction.
For the effectiveness strength rating, the point estimate from each study between ≤1 and 
≤2.0 was considered as a “moderate” magnitude of effectiveness; and any point estimate 
>2.0 was considered a “substantial” magnitude of effect. Final conclusions and 
recommendations for the overall effectiveness were based on the criteria including number 
of studies, quality of available evidence, consistency of results, and magnitude of effect 
estimates. Criteria for these ratings are described in greater detail elsewhere (43).
RESULTS
A total of 5575 bibliographic records were retrieved from the literature search, of which 106 
were identified from other sources (e.g., hand searches, referrals). A total of 5305 studies 
were excluded (2044 duplicates and 3261 were not relevant to the topic). The remaining 270 
published studies were screened further, and 179 were excluded. The remaining 91 studies 
were subjected to full abstraction and quality assessment; finally, 9 independent published 
studies (34, 46–53) met the inclusion criteria and comprised the total body of evidence (Fig. 
2).
Apo B
Four eligible studies (48, 49, 51, 52) examined the associations between the plasma apo B 
levels when added to other traditional lipids with CVD risk prediction. The combined 
evidence from all included studies indicated that the risk assessment to develop long-term 
CVD events was significantly improved by adding apo B marker to the traditional risk 
factors (overall effect = relative risk: 1.31, 95% CI, 1.22–1.40, Fig. 3). The total evidence 
showed consistently favorable association of apo B lipid marker with the better long-term 
CVD risk prediction. The effect estimates for the CVD risk prediction were statistically 
significant from all included studies (48, 49, 52) but 1 study (51). The overall evidence was 
derived from 3 good quality studies (49, 51, 52) and 1 “fair” quality study (48) (Fig. 3).
Conclusions—Applying the LMBP criteria (43), the overall strength of evidence is 
considered moderate to conclude that the addition of apo B bio-marker to the traditional risk 
factors can improve the risk prediction for cardiovascular events for populations at risk 
(Table 1).
LMBP working group (WG) recommendation (apo B)—Based on the moderate 
evidence of effectiveness, lipoprotein apo B measure is recommended to improve the risk 
prediction for cardiovascular events when added to other traditional risk factors for the 
populations at risk (e.g., men >35 years, women >45 years, and younger adults ≥20 years 
old with multiple risk factors for CVD, in ambulatory and inpatient settings). This 
recommendation is based on consistently favorable results from 3 “good” quality and 1 fair 
quality studies.
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Apo A-I
Two studies (48, 49) qualified to be included in the evidence that reported the impact of the 
measures of apo A-I in CVD risk prediction. One study was rated good quality of execution 
(49) and the other study was of fair quality (48). Combined results from both studies showed 
the favorable association of apo A-I marker with the CVD risk prediction—that is, the 
participants with the higher apo A-I levels tended to have lower risk of developing CVD 
events (overall random effect: 0.85; 95% CI, 0.79–0.92) (Fig. 4).
Conclusions—Applying the LMBP criteria, due to the limited available evidence, the 
overall strength of evidence is considered “insufficient” to conclude that the addition of apo 
A-I to the traditional risk factors can improve the risk prediction for cardiovascular events 
for populations at risk.
LMBP WG recommendation (apo A-I)—Because of the insufficient available evidence, 
no recommendations could be made for or against the effectiveness of apo A-I practices to 
predict the CVD events.
Apo B/apo A-I
Seven studies provided evidence for the effectiveness of apo B/A-I ratio. Results from 4 
included studies (46, 47, 50, 51) were presented as hazard ratios, 2 as relative risk (34, 48), 
and 1 as odds ratio (53); the results from these studies were combined to calculate overall 
grand mean estimate of effectiveness. The combined results from the total evidence showed 
a consistent and positive association of apo B/A-I ratio marker to the development of long-
term CVD events [overall grand mean estimate: 1.31 (95% CI, 1.11–1.38)] (Fig. 5). The 
results were statistically significant from all but 2 studies (47, 51). Of 7 studies, 4 studies 
(34, 47, 50, 51) had a quality rating of good, and 3 (46, 48, 53) were of fair quality. One 
study (50) showed a substantial effect estimate but had a large CI, indicating a less precise 
estimate. Six studies (34, 46–48, 51, 53) showed moderate effect for the CVD risk prediction 
(Fig. 5).
Conclusions—Applying the LMBP criteria, the overall strength of evidence is considered 
moderate to conclude that the addition of apo B/apo I ratio to the traditional risk factors can 
improve the risk prediction for cardiovascular events for populations at risk (Table 2).
LMBP WG recommendation (apo B/apo A-I ratio)—According to the LMBP 
methods, based on the moderate evidence of effectiveness the lipo-protein apo B/apo A-I 
ratio is recommended to improve the risk prediction for cardiovascular events when added to 
other traditional risk factors for the populations at risk (e.g., men >35 years, women >45 
years, younger adults ≥20 years old with multiple risk factors for CVD, in ambulatory and 
inpatient settings). This recommendation is developed based on evidence from 4 good and 3 
fair quality studies (Table 2).
Non-HDL-C
Only 1 fair quality study (48) was identified investigating the association of non-HDL-C 
with CVD outcomes after controlling for traditional risk factors. The results from this 
Sandhu et al. Page 8
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
prospective cohort study showed that non-HDL-C lipid marker when adjusted for nonlipid 
(e.g., age, sex) and lipid (e.g., triglycerides) risk factors were associated with better CVD 
risk prediction at the 7.9-year follow-up period (hazard ratio: 1.25; 95% CI, 1.11–1.41).
Conclusions—Applying the LMBP criteria (43), the overall strength of evidence is 
considered insufficient to conclude at the time that the measures of non-HDL-C can improve 
the risk prediction for cardiovascular events for populations at risk.
LMBP WG recommendation (non-HDL-C)—Because of the insufficient available 
evidence, no recommendations could be made for or against the effectiveness of non-HDL-C 
practices to predict the CVD events (Table 3).
DISCUSSION
Best practices recommendations
Based on the findings from this systematic review, below are the LMBP workgroup 
recommendations for 4 evaluated practices in this review.
Lipoprotein apo B and apo B/apo A-I ratio measures are recommended to improve the risk 
pre-diction for cardiovascular events when added to other traditional risk factors for the 
populations at risk (i.e., men >35 years, women >45 years, and younger adults ≥20 years old 
with multiple risk factors for CVD, in ambulatory and inpatient settings).
Because of the insufficient evidence, no recommendations could be made for or against their 
effectiveness of apo A-I and non-HDL-C practices to improve the prediction of CVD events. 
This result does not discount the utility of these lipid markers in this context, but points to 
the lack of sufficient and consistent evidence in the literature. This is partly driven by the 
fact that many studies had to be excluded from the analyses because they did not include or 
adjust for all of the traditional risk factors included in this review.
This review examined 4 nontraditional lipid bio-markers, namely apo B, apo A-I, apo B/A-I 
ratio, and non-HDL-C, for improving CVD risk assessment. In contrast to previous 
guidelines, to date, some published reviews focus on 1 biomarker (22, 54) whereas others 
examine several biomarkers (3, 31, 55). The intent of the current review was not to 
determine how well the lipid biomarkers predict the risk of CVD in comparison to or as a 
replacement to traditional lipid and nonlipid risk factors, but rather, how do these emerging 
lipoproteins improve the risk prediction for CVD when added to traditional cardiovascular 
risk factors.
The lipid biomarkers examined in this review have great potential utility in the field of 
cardiovascular health and have been investigated for at least 2 decades. Undoubtedly, the 
literature is available to answer different types of review questions in this field. Based on the 
existing evidence, major Canadian guideline groups have concluded that specific 
apolipoproteins should be included into CVD screening biomarkers as an alternative to the 
traditional cholesterol indices to estimate risk and to guide therapy (56, 57). Yet, limited 
evidence was available to answer our review question, “Did the lipid biomarker provide 
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additional benefit beyond traditional risk factors?” Our findings are consistent with current 
national guidelines in the use of apo B (55). We extend and add to those findings by 
investigating the use of other lipid biomarkers (apo A-I, apo B/A-I ratio, and non-HDL-C), 
which, to the best of our knowledge, have not been assessed in the same review and 
subjected to the same rigorous review criteria. It is important to acknowledge that the 
practices and outcomes used in this systematic review agree with the general principles of, 
but do not necessarily mimic, the current (ATP [Adult Treatment Panel] IV) (55) and past 
(ATP III) (58) guidelines for CVD risk prevention in the general population. The approach 
for this review was intended to be independent and stand alone and was thoroughly 
evaluated with guidance from the expert panel. This review was initiated while ATP III 
guidelines were enacted; the ATP IV guidelines were published towards the end. The 
traditional risk factors used in this review are in common with those assessed in both 
guidelines and are considered standard practice. For the applicability of the review, 
substantial and moderate findings were reported from Sweden (50), the US (46, 47, 50, 51), 
Canada (49, 52), the Netherlands (48, 53), and Denmark (58). In contrast, ATP IV guidelines 
(55) report risk equations from a pooled population of non-Hispanic African Americans and 
whites. Several studies reviewed herein provided promising results.
Considerations for implementation
Apo B is measured mainly by immunonephelometric or immunoturbidimetric assays. Efforts 
to improve variability among these assays have been made by harmonizing measurements 
using a thoroughly characterized immunoassay. Because apo B is a well-characterized 
analyte, it has the potential of being standardized and linked to the International System of 
Units (SI system), which is not possible with LDL-C, which is often only indirectly 
measured and harmonized to a thoroughly characterized ultracentrifugation method (16, 33, 
60, 61). Like apo B, apo A-I is mainly measured with immunonephelometric or 
immunoturbidimetric assays. These assays are being harmonized to a thoroughly 
characterized immunoassay, while HDL-C (2) assays are standardized to a thoroughly 
characterized ultracentrifugation method (23, 33, 61). Non-HDL-C is simply calculated as 
the difference between total plasma cholesterol and HDL-C. Since it can be calculated 
directly from routine lipid tests, it does not incur additional cost, making it more readily 
available (54, 62). Since non-HDL-C does not depend on triglycerides, it can be calculated 
from nonfasting samples.
Economic evaluation
No eligible economic evaluations were identified for analysis of cost-effectiveness.
Potential harms
The use of additional lipid biomarkers could require an additional venipuncture. All 
venipuncture procedures pose a minimal risk to clinical staff of needle stick injury and 
exposure to infectious or other harmful agents. In addition, patients identified at intermediate 
risk to develop CVD events may become candidates for unnecessary additional testing to 
better stratify risk and for aggressive medical therapy (e.g., lipid lowering, blood pressure 
control) for secondary CVD prevention (63).
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Study limitations
The scope and clinical relevance of this review is confined to CVD events and excludes 
stroke, which has been included in the outcome for CVD risk assessment in the recent 
national guidelines for assessment of cardiovascular risk (55). Most of the evidence for this 
review is from prospective studies with populations having a single race/ethnicity, thus 
limiting generalizability. However, across the studies, there was a variety of findings 
supporting the need to develop population-specific risk prediction systems. In some cases, 
the follow-up period was <10 years, which may introduce bias into the case ascertainment 
process. However, this concern was compensated during the quality scoring of these studies. 
Differences in inherent or baseline risk status may arise from the type of population used in 
the studies (community based vs clinic based), which may affect study results. In addition, 
the restriction to English language studies may also introduce bias.
Several studies summarized in this review did not control for variations in measurement 
method and interindividual variation—for example, this review assumed that all biomarker 
tests used in individual studies performed at the same level of analytical quality. The impact 
of these differences on the outcome of this review is not known.
Future research needs
There was sufficient evidence to make recommendations for 2 risk biomarkers based on the 
moderate strength of evidence. However, more research is needed to strengthen the evidence 
rating and also to make recommendations for the other 2 biomarkers (e.g., apo A-I and non-
HDL-C). Examination of the literature revealed several deficits that need to be highlighted 
as best practices for high-quality studies examining the added benefit of nontraditional lipid 
biomarkers to predicting CVD events. Several studies did not adjust for all the traditional 
risk factors and provided incomplete information about the demographics of the population. 
Model descriptions varied, and in some cases, it was difficult to understand the model 
selection criteria, model specifications, and what factors were included in the model. Several 
studies lacked sufficient raw data eliminating the ability to replicate findings. Finally, many 
studies used different analytical methods to calculate the effectiveness of evaluated 
practices; thus, we were not able to combine the result from those studies to perform 
metaanalysis to produce an overall grand mean of effectiveness. It is desirable for future 
studies to use common standardized analytical methods.
The aim of this study was to assess the additive benefits obtained by adding the lipid 
biomarkers to a panel of traditional risk factors. Thus, the potential benefits of replacing the 
traditional risk factors with the new biomarkers, especially in patients with conditions 
known to have highly altered lipid particle profiles, was not assessed and requires further 
investigation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Sandhu et al. Page 11
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
This work was funded by the CDC under contract number SP0700-00-D-3180, Delivery Order 0723, “Laboratory 
Medicine Preparedness: Best Practices.” Names and affiliations of LMBP Workgroup can be found at http://
wwwn.cdc.gov/futurelabmedicine/default.aspx. The authors recognize Melissa Gustafson (Battelle Librarian), 
LMBP CVD Biomarkers Expert Panel, LMBP Workgroup members, and Joanna Taliano, Reference Librarian 
(CDC).
References
1. World Health Organization. [Accessed July 2016] Fact sheet: Cardiovascular diseases (CVDs). 
2014. http://www.who.int/mediacentre/factsheets/fs317/en/
2. Force USPST. The Guide to Clinical Preventive Services 2010–2011: Recommendations of the U.S. 
Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality 
(US); 2010. US Preventive Services Task Force Guides to Clinical Preventive Services. 
3. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA 
guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Coll Cardiol. 2010; 56:e50–103. [PubMed: 21144964] 
4. Laslett LJ, Alagona PBL Jr, Clark BABL 3rd, Drozda JPBL Jr, Saldivar F, Wilson SR, et al. The 
worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: 
a report from the American College of Cardiology. J Am Coll Cardiol. 2012; 60(25 Suppl):S1– 49. 
[PubMed: 23257320] 
5. Arsenault BJ, Despres JP, Stroes ES, Wareham NJ, Kastelein JJ, Khaw KT, et al. Lipid assessment, 
metabolic syndrome and coronary heart disease risk. Eur J Clin Invest. 2010; 40:1081–93. 
[PubMed: 20701625] 
6. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al. Lipids and lipoproteins and risk 
of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012; 125:2469–
78. [PubMed: 22539783] 
7. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of 
the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in 
Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart 
J. 2012; doi: 10.1093/eurheartj/ehs092
8. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for 
evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart 
Association. Circulation. 2009; 119:2408–16. [PubMed: 19364974] 
9. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction 
models: I. Development, internal validation, and assessing the incremental value of a new 
(bio)marker. Heart. 2012; 98:683–90. [PubMed: 22397945] 
10. Clarke R, Emberson JR, Parish S, Palmer A, Shipley M, Linksted P, et al. Cholesterol fractions and 
apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med. 2007; 
167:1373– 8. [PubMed: 17620530] 
11. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, Wojta J, et al. Relative importance of 
different lipid risk factors for the development of myocardial infarction at a very young age (≤40 
years of age). Eur J Clin Invest. 2012; 42:631–6. [PubMed: 22150092] 
12. Langlois MR. Laboratory approaches for predicting and managing the risk of cardiovascular 
disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med. 2012; 
50:1169–81. [PubMed: 22850050] 
13. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of Obesity Among Adults and Youth: 
United States, 2011–2014. NCHS Data Brief. 2015; (219):1–8.
14. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, et al. Clinical 
utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of 
lipid specialists. J Clin Lipidol. 2011; 5:338–67. [PubMed: 21981835] 
Sandhu et al. Page 12
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Sniderman AD, De Graaf J, Couture P. Low-density lipoprotein-lowering strategies: target versus 
maximalist versus population percentile. Curr Opin Cardiol. 2012; 27:405–11. [PubMed: 
22573170] 
16. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin 
Cardiol. 2009; 32:482–6. [PubMed: 19743499] 
17. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual 
cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008; 14(8 Suppl):S3–28. 
quiz S30–1. 
18. Dallmeier D, Koenig W. Strategies for vascular disease prevention: the role of lipids and related 
markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity 
C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA(2)) and 
lipoprotein(a) (Lp(a)). Best Pract Res Clin Endocrinol Metab. 2014; 28:281–94. [PubMed: 
24840259] 
19. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary 
prevention of cardiovascular disease: a systematic review. Heart. 2006; 92:1752–9. [PubMed: 
16621883] 
20. Jackson R, Kerr A, Wells S. Vascular risk calculators: essential but flawed clinical tools? 
Circulation. 2013; 127:1929–31. [PubMed: 23580778] 
21. Benn M, Stene MC, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. Common 
and rare alleles in apolipoprotein B contribute to plasma levels of low-density lipoprotein 
cholesterol in the general population. J Clin Endocrinol Metab. 2008; 93:1038–45. [PubMed: 
18160469] 
22. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, et al. Apolipoprotein B 
and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular 
Diseases Division Working Group on Best Practices. Clin Chem. 2009; 55:407–19. [PubMed: 
19168552] 
23. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease 
and a target for lipid-lowering therapy–A review of the evidence. J Intern Med. 2006; 259:493–
519. [PubMed: 16629855] 
24. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with 
alternative LDL-related measures and future coronary events. Circulation. 2014; 129:553–61. 
[PubMed: 24345402] 
25. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and 
non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART 
study. Atherosclerosis. 2012; 225:444–9. [PubMed: 23068583] 
26. Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, et al. Lipid-related 
markers and cardiovascular disease prediction. JAMA. 2012; 307:2499–506. [PubMed: 22797450] 
27. Gigante B, Leander K, Vikstrom M, Frumento P, Carlsson AC, Bottai M, et al. Elevated ApoB 
serum levels strongly predict early cardiovascular events. Heart. 2012; 98:1242–5. [PubMed: 
22760866] 
28. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and 
risk of myocardial infarction: age, gender and short versus longer follow-up periods in the 
Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2008; 264:30–8. [PubMed: 
18298486] 
29. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the 
prediction of myocardial infarction in middle-aged men and women: results from the MONICA/
KORA Augsburg cohort study. Eur Heart J. 2005; 26:271–8. [PubMed: 15618061] 
30. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of 
lipid parameters as predictors of coronary heart disease among postmenopausal women: potential 
implications for clinical guidelines. Circulation. 2004; 110:2824–30. [PubMed: 15492318] 
31. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-
analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and 
apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4:337–
45. [PubMed: 21487090] 
Sandhu et al. Page 13
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
32. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low 
apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS 
study): A prospective study. Lancet. 2001; 358:2026–33. [PubMed: 11755609] 
33. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B 
plasma levels. J Intern Med. 2006; 259:437–46. [PubMed: 16629849] 
34. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio 
is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and 
antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004; 42:1355–63. 
[PubMed: 15576296] 
35. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome 
independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb 
Vasc Biol. 2006; 26:406–10. [PubMed: 16306426] 
36. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, 
lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the 
INTERHEART study): a case-control study. Lancet. 2008; 372:224–33. [PubMed: 18640459] 
37. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the 
TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of 
vascular disease. J Intern Med. 2006; 259:455–61. [PubMed: 16629851] 
38. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein 
cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization 
Investigation (BARI). Circulation. 2002; 106:2537–42. [PubMed: 12427648] 
39. Ghosh J, Mishra TK, Rao YN, Aggarwal SK. Oxidised LDL, HDL cholesterol, LDL cholesterol 
levels in patients of coronary artery disease Indian. J Clin Biochem. 2006; 21:181–4.
40. Kumar A, Nagtilak S, Sivakanesan R, Gunasekera S. Cardiovascular risk factors in elderly 
normolipidemic acute myocardial infarct patients–A case controlled study from India. Southeast 
Asian J Trop Med Public Health. 2009; 40:581–92. [PubMed: 19842447] 
41. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and 
LDL cholesterol and coronary heart disease risk prediction among individuals with and without 
diabetes. Diabetes Care. 2005; 28:1916–21. [PubMed: 16043732] 
42. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein 
cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 
2005; 112:3375–83. [PubMed: 16316964] 
43. Christenson RH, Snyder SR, Shaw CS, Derzon JH, Black RS, Mass D, et al. Laboratory medicine 
best practices: systematic evidence review and evaluation methods for quality improvement. Clin 
Chem. 2011; 57:816–25. [PubMed: 21515742] 
44. Prinja S, Gupta N, Verma R. Censoring in clinical trials: review of survival analysis techniques. 
Indian J Community Med. 2010; 35:217–21. [PubMed: 20922095] 
45. Borenstein, MHL.; Higgins, JPT.; Rothstein, HR. Introduction to meta-analysis. Chichester (UK): 
Wiley; 2009. 
46. Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors 
for heart failure. J Am Coll Cardiol. 2005; 46:2054–60. [PubMed: 16325042] 
47. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility 
of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 
2007; 298:776–85. [PubMed: 17699011] 
48. Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbuttel BH, Dullaart RP. Apolipoprotein B/A-I and 
total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in 
the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J 
Intern Med. 2011; 269:232–42. [PubMed: 21129046] 
49. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein 
A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the 
Quebec cardiovascular study. Circulation. 1996; 94:273–8. [PubMed: 8759066] 
50. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. 
Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I 
ratio and better than routine clinical lipid measurements in predicting coronary heart disease 
Sandhu et al. Page 14
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
mortality: Findings from a multi-ethnic US population. Eur Heart J. 2009; 30:710–7. [PubMed: 
18676970] 
51. Steffen BT, Guan W, Remaley AT, Paramsothy P, Heckbert SR, McClelland RL, et al. Use of 
lipoprotein particle measures for assessing coronary heart disease risk post-American Heart 
Association/American College of Cardiology guidelines: The Multi-Ethnic Study of 
Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015; 35:448–54. [PubMed: 25477346] 
52. St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Apolipoprotein-B, low-density 
lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol. 
2006; 97:997–1001. [PubMed: 16563904] 
53. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, et al. Role 
of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: A case-control 
analysis in EPIC-Norfolk. Ann Intern Med. 2007; 146:640–8. [PubMed: 17470832] 
54. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. The importance of non-HDL cholesterol 
reporting in lipid management. J Clin Lipidol. 2008; 2:267–73. [PubMed: 21291742] 
55. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. 2013 
ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2014; 63:2935–59. [PubMed: 24239921] 
56. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of 
the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia 
for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013; 29:151–67. 
[PubMed: 23351925] 
57. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of 
dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 
2003; 169:921–4. [PubMed: 14581310] 
58. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final 
report. Circulation. 2002; 106:3143–421. [PubMed: 12485966] 
59. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic 
cardiovascular disease in the general population using apolipoprotein B: The Copenhagen City 
Heart Study. Arterioscler Thromb Vasc Biol. 2007; 27:661–70. [PubMed: 17170368] 
60. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven 
direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation 
reference measurement procedures. Clin Chem. 2010; 56:977–86. [PubMed: 20378768] 
61. Rifai, NWG.; Dominiczak, MH. Handbook of lipoprotein testing. Washington (DC): AACC Press; 
1997. 
62. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus 
apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011; 
58:457–63. [PubMed: 21777740] 
63. Smith SC Jr, Amsterdam E, Balady GJ, Bonow RO, Fletcher GF, Froelicher V, et al. Prevention 
Conference V: Beyond secondary prevention: identifying the high-risk patient for primary 
prevention: tests for silent and inducible ischemia: Writing Group II. Circulation. 2000; 101:E12–
6. [PubMed: 10618317] 
Sandhu et al. Page 15
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IMPACT STATEMENT
The findings from this study are beneficial for the population at risk of developing 
adverse cardiovascular events, including men (>35 years), women (>45 years), and 
younger adults (≥20 years) with multiple cardiovascular risk factors for cardiovascular 
disease (CVD). Existing guidelines mainly used traditional lipid levels and other risk 
factors—namely total cholesterol, LDL, HDL, triglycerides, high blood pressure, 
smoking, diabetes, age, and sex—as risk factor scores for CVD risk prediction. This 
study evaluated the incremental utility of nontraditional lipid biomarkers (e.g., apo B, apo 
A-I, and non-HDL-C) in improving CVD risk prediction to a conventional model of 
traditional risk factors.
Sandhu et al. Page 16
J Appl Lab Med. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Analytic framework.
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Fig. 2. 
Biomarkers and risk of CVD review search flow diagram.
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Fig. 3. 
Risk prediction for CVD events due to apo B vs other traditional risk factors.
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Fig. 4. 
Risk prediction for CVD events due to apo A-I vs other traditional risk factors.
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Fig. 5. 
Risk prediction for CVD events due to apo B/apo A-I ratio vs other traditional risk factors.
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Table 1
Body of evidence LMBP ratings for apo B.
Study, year Study quality rating Effect size rating
Steffen et al., 2015 Good Moderate
Kappelle et al., 2011 Fair Moderate
St-Pierre et al., 2006 Good Moderate
Lamarche et al., 1996 Good Moderate
Body of evidence ratings 1 Fair/moderate
3 Good/moderate
Consistency Yes
Overall strength Moderate
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Table 2
Body of evidence LMBP ratings for apo B/A-I.
Study, year Study quality rating Effect size rating
Steffen et al., 2015 Good Moderate
Kappelle et al., 2011 Fair Moderate
Sierra-Johnson et al., 2009 Good Substantial
Ingelsson et al., 2007 Good Moderate
van der Steeg et al., 2007 Fair Moderate
Ingelsson et al., 2005 Fair Moderate
Walldius et al., 2004 Good Moderate
Body of evidence ratings 1 Good/substantial
3 Good; 3 fair/moderate
Consistency Yes
Overall strength Moderate
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Table 3
Body of evidence LMBP ratings for non-HDL-C.
Study, year Study quality rating Effect size rating
Kappelle, 2011 Fair Moderate
Body of evidence ratings 1 Fair/moderate
Consistency Not applicable
Overall strength Insufficient
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